TORONTO, ONTARIO–(Marketwired – Nov. 2, 2016) – Bradmer Pharmaceuticals Inc. (“Bradmer” or the “Company”) (NEX:BMR.H) today announced its third quarter 2016 financial results.
Financial Results
Amounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards (“IFRS”).
For the three months ended September 30, 2016, we recorded a net loss of $20,000 or $0.001 per common share based on the weighted average outstanding shares of 19,659,726 during the three month period, compared to net income of $3,000 or $0.0001 per common share for the quarter ended September 30, 2015 based on the weighted average outstanding shares of 19,659,726.
General and administrative expenses were $24,000 in the three months ended September 30, 2016 compared to $25,000 in the same quarter of the prior year. Major expenses in 2016 consisted of consulting fees of $14,000, legal fees of $3,100, audit fees of $2,300 and directors’ and officers’ liability insurance premiums of $2,400. Expenses in 2015 consisted of consulting fees of $14,000, legal fees of $4,000, directors’ and officers’ liability insurance premiums of $3,000 and audit fees of $2,000.
The $3,000 foreign exchange gain in the third quarter of 2016 compared with the $28,000 foreign exchange gain in the same quarter of 2015.
For the nine months ended September 30, 2016, we recorded a net loss of $114,000 or $0.006 per common share based on the weighted average outstanding shares of 19,659,726 during the nine month period, compared to a net loss of $53,000 or $0.003 per common share for the nine months ended September 30, 2015 based on the weighted average outstanding shares of 19,659,726.
General and administrative expenses were $92,000 in the nine months ended September 30, 2016 compared to $110,000 in the same period of the prior year. Major expenses in 2016 consisted of consulting fees of $41,000, legal fees of $23,000, transfer agent and stock exchange listing fees of $10,000, audit fees of $7,000 and insurance premiums of $7,000. Expenses in 2015 consisted of a work fee from WCM Capital of $20,000, consulting fees of $43,000, legal fees of $20,000, audit fees of $8,000, transfer agent and stock exchange listing fees of $7,000 and insurance premiums of $9,000.
A $22,000 foreign exchange loss in the first nine months of 2016 compared with a $56,000 foreign exchange gain in the prior year period.
Bradmer’s operational activities for the nine months ended September 30, 2016 were financed by cash on hand. At September 30, 2016, we had working capital of $412,000, compared to $500,000 at December 31, 2015. We had available cash of $448,000 (CDN $588,000) as at September 30, 2016, compared to cash of $521,000 (CDN $721,000) as at December 31, 2015. The $73,000 decrease in cash was due to the $114,000 net loss offset by $26,000 of foreign currency translation adjustments and $15,000 in working capital changes.
As at November 2 and September 30, 2016, the Company had 19,659,726 common shares and options to purchase 1,950,000 common shares outstanding.
Additional information about Bradmer, including the MD&A and financial results may be found on SEDAR at www.sedar.com.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Bradmer’s common shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.
Except for historical information, this news release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Financial Position As at
(All amounts expressed in United States dollars)
| September 30, | December 31, | ||||||
| 2016 | 2015 | ||||||
| (Audited | ) | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash | $ | 447,939 | $ | 520,758 | |||
| Amounts receivable | 7,771 | 5,098 | |||||
| Prepaid expenses | 6,612 | 1,268 | |||||
| Total assets | $ | 459,322 | $ | 527,124 | |||
| Liabilities and Shareholders’ Equity | |||||||
| Current liabilities | |||||||
| Accounts payable and accrued liabilities | $ | 47,091 | $ | 27,039 | |||
| Shareholders’ Equity | |||||||
| Share capital | 1,750,554 | 1,659,105 | |||||
| Contributed surplus | 1,934,416 | 1,833,363 | |||||
| Accumulated other comprehensive income | 819,699 | 985,568 | |||||
| Deficit | (4,092,438 | ) | (3,977,951 | ) | |||
| Total shareholders’ equity | 412,231 | 500,085 | |||||
| Total liabilities and shareholders’ equity | $ | 459,322 | $ | 527,124 | |||
BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Comprehensive Income For the three and nine months ended September 30
(All amounts expressed in United States dollars)
| Nine Months Ended | Three Months Ended | |||||||||||||||
| September 30 | September 30 | |||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| Expenses | ||||||||||||||||
| General and administrative | $ | 92,375 | $ | 109,654 | $ | 23,597 | $ | 24,961 | ||||||||
| (92,375 | ) | (109,654 | ) | (23,597 | ) | (24,961 | ) | |||||||||
| Other Income | ||||||||||||||||
| Interest | 87 | 89 | 29 | 19 | ||||||||||||
| Foreign exchange (loss)/gain | (22,199 | ) | 56,241 | 3,146 | 27,521 | |||||||||||
| (22,112 | ) | 56,330 | 3,175 | 27,540 | ||||||||||||
| (Loss)/income for the period | $ | (114,487 | ) | $ | (53,324 | ) | $ | (20,422 | ) | $ | 2,579 | |||||
| Other comprehensive (loss)/income | (165,869 | ) | 460,857 | 27,471 | 215,105 | |||||||||||
| Comprehensive (loss)/income for the | ||||||||||||||||
| period | $ | (280,356 | ) | $ | 407,533 | $ | 7,050 | $ | 217,684 | |||||||
| (Loss)/income per share | ||||||||||||||||
| Basic and diluted | $ | (0.006 | ) | $ | (0.003 | ) | $ | (0.001 | ) | $ | 0.000 | |||||
| Weighted average number | ||||||||||||||||
| of shares outstanding | 19,659,726 | 19,659,726 | 19,659,726 | 19,659,726 | ||||||||||||
BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Changes in Shareholders’ Equity For the nine months ended September 30
(All amounts expressed in United States dollars)
| Accumulated Other Comprehensive Income/ (Loss) |
Deficit |
Total Shareholders’ equity |
||||||||||||||
| Share capital | ||||||||||||||||
| Number of shares |
Amount | Contributed surplus |
||||||||||||||
| Balance, January 1, 2015 | 19,659,726 | $ | 1,979,314 | $ | 2,187,203 | $ | 414,186 | $ | (3,917,801 | ) | $ | 662,902 | ||||
| Foreign currency translation | ||||||||||||||||
| adjustment | – | (256,668 | ) | (285,836 | ) | 460,857 | – | (83,647 | ) | |||||||
| Loss for the period | – | – | – | – | (53,324 | ) | (53,324 | ) | ||||||||
| Balance, September 30, 2015 | 19,659,726 | $ | 1,720,646 | $ | 1,901,367 | $ | 875,043 | $ | (3,971,125 | ) | $ | 523,931 | ||||
| Balance, January 1, 2016 | 19,659,726 | $ | 1,659,105 | $ | 1,833,363 | $ | 985,568 | $ | (3,977,951 | ) | $ | 500,085 | ||||
| Foreign currency translation | ||||||||||||||||
| adjustment | – | 91,449 | 101,053 | (165,869 | ) | – | 26,633 | |||||||||
| Loss for the period | – | – | – | – | (114,487 | ) | (114,487 | ) | ||||||||
| Balance, September 30, 2016 | 19,659,726 | $ | 1,750,554 | $ | 1,934,416 | $ | 819,699 | $ | (4,092,438 | ) | $ | 412,231 | ||||
BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Cash Flows For the nine months ended September 30
(All amounts expressed in United States dollars)
| 2016 | 2015 | ||||||||
| Cash flows from operating activities | |||||||||
| Loss for the period | $ | (114,487 | ) | $ | (53,324 | ) | |||
| Adjustment for: | |||||||||
| Foreign currency translation adjustment | 20,950 | (83,647 | ) | ||||||
| (93,537 | ) | (136,971 | ) | ||||||
| Change in non-cash operating items | |||||||||
| Amounts receivable | (2,673 | ) | (2,033 | ) | |||||
| Prepaid expenses | (2,344 | ) | (2,200 | ) | |||||
| Accounts payable and accrued liabilities | 20,052 | (10,214 | ) | ||||||
| (78,502 | ) | (151,417 | ) | ||||||
| Effect of exchange rate fluctuations on cash held | 5,684 | – | |||||||
| Decrease in cash | (72,819 | ) | (151,417 | ) | |||||
| Cash at beginning of period | 520,758 | 699,158 | |||||||
| Cash at end of period | $ | 447,939 | $ | 547,741 | |||||
Paul Van Damme
Chief Financial Officer
pvandamme@wcmcapital.ca
1.416.847.6905